CureVac Shares Cease Trading Following BioNTech Acquisition

CureVac NL0015436031

The independent public market journey of German mRNA specialist CureVac has concluded. As of today, January 16, 2026, the company's shares are no longer listed on any stock exchange, marking the final step in its acquisition by fellow German biotech firm BioNTech. The ticker symbol "CVAC" has been permanently removed from the Nasdaq, where it was formerly traded.

The path to this delisting began with an agreement announced in June 2025. BioNTech valued CureVac at approximately $1.25 billion in an all-stock transaction. The exchange offer closed on December 18, 2025, having attracted 195,341,219 CureVac shares, representing 86.75% of the outstanding capital.

Key terms of the completed deal include:

• Exchange Ratio: 0.05363 BioNTech American Depositary Shares (ADS) for each CureVac share.
• Implied Value: This ratio translated to a value of $5.46 per CureVac share at the time of the initial announcement.
• Acquisition Completion: The takeover was formally completed on January 6, 2026.
• Delisting Effective Date: The official removal from the Nasdaq occurred today, January 16, 2026.

The remaining minority holdings were transferred to BioNTech in early January via a squeeze-out procedure. Legally, the entity CureVac Merger B.V. has now replaced the former CureVac SE through a statutory merger.

Trading Halt Preceded Final Delisting

Trading in CureVac securities was actually suspended prior to the market open on January 6, 2026, immediately following the completion of the restructuring. The company notified the Nasdaq of the closed transaction and simultaneously filed a Form 25 with the U.S. Securities and Exchange Commission (SEC) to initiate the formal delisting process.

The Vienna Stock Exchange had already halted trading in CureVac papers on January 7, 2026. With these actions, no publicly tradable CureVac shares remain, and there are no longer any free float shareholders.

Looking Ahead: Deregistration Process

The next administrative step involves CureVac Merger B.V. filing a Form 15 with the SEC. This submission will seek to terminate the registration of CureVac shares under Section 12(g) of the U.S. Exchange Act and suspend all ongoing reporting obligations. A full deregistration is anticipated roughly 90 days after the form is filed.

Strategic Rationale: Uniting mRNA Expertise

This acquisition consolidates two pioneering German companies in the messenger RNA field under the BioNTech umbrella. BioNTech gains access to CureVac's proprietary technology platform, which includes its "RNA Printer" production modules and oncology development pipeline.

The supervisory board of CureVac SE now comprises Prof. Ugur Sahin, Sierk Poetting, and Ramón Zapata-Gomez. CureVac's previous management team resigned in its entirety upon the transaction's completion.

For the immediate integration phase, BioNTech intends to maintain CureVac's existing operational workflows. Subsequent decisions regarding the future organizational structure and development portfolio will be made following comprehensive strategic, operational, and scientific reviews.